Lack of very strong association between pre-treatment fibrinogen and PAI-1 with long-term mortality after coronary bypass surgery

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift


Aim: To explore the association between the coagulation protein fibrinogen and the fibrinolytic biomarker plasminogen activator inhibitor-1 ( PAI- 1) and the long- term mortality after coronary artery bypass grafting ( CABG). Patients and Methods: In 729 patients undergoing CABG at Sahlgrenska University Hospital, a blood sample for fibrinogen and PAI-1 was collected prior to the procedure. Patients were followed for 10 years. Results: Among patients with high levels of fibrinogen (> 3.6 g/ l; median), the 10-year mortality was 32.3 vs. 20.7% among patients with fibrinogen levels below the median ( p = 0.0005). However, patients with higher levels of fibrinogen were older and had an adverse risk factor pattern. When adjusting for these differences, pre- operative fibrinogen levels did not clearly appear as an independent predictor of long- term mortality. The 10- year mortality was similar in patients with high ( 25.3%) and low ( 26.5%) levels of PAI-1. Conclusion: Our results do not suggest that fibrinogen and PAI- 1, when evaluated prior to the operative procedure, arestrongly associated with increased mortality in the longterm after CABG, when other co-morbidity factors are simultaneously considered.


Enheter & grupper

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Kardiologi


Sidor (från-till)82-89
Utgåva nummer2
StatusPublished - 2007
Peer review utfördJa